Improving topical non-melanoma skin cancer treatment: In vitro efficacy of a novel guanosine-analog phosphonate

Skin Pharmacology and Physiology

Volumn 27, Issue 4, 2014, Pages 173-180

  Ali Von Laue, C ^a   Zoschke, C ^a   Do, N ^a   Lehnen, D ^a   Kuchler S ^a   Mehnert, W ^a   Blaschke, T ^a   Kramer, K D ^a   Plendl, J ^a   Weindl, G ^a   Korting, H C ^b   Hoeller Obrigkeit, D ^c   Merk, H F ^c   Schafer Korting M ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Drug delivery systems; Keratin 18; Non melanoma skin cancer; Preclinical drug development; Purine nucleotide analogues; Tissue engineering; Topical administration

Indexed keywords

CASPASE 7; CYTOKERATIN 18; FLUOROURACIL; GELATINASE A; KI 67 ANTIGEN; OXBU; PURINE NUCLEOTIDE; SOLID LIPID NANOPARTICLE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; GUANOSINE; NANOPARTICLE; PHOSPHONIC ACID DERIVATIVE;

ACTINIC KERATOSIS; APOPTOSIS; ARTICLE; CANCER THERAPY; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; FIBROBLAST; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IN VITRO STUDY; KERATINOCYTE; NON MELANOMA SKIN CANCER; PRIORITY JOURNAL; SKIN PENETRATION; TISSUE ENGINEERING; TOPICAL TREATMENT; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG SCREENING; DRUG STABILITY; ENZYME ACTIVATION; HUMAN TISSUE; LIMIT OF QUANTITATION; LOADING DRUG DOSE; MOLECULAR SIZE; NANOENCAPSULATION; SCANNING ELECTRON MICROSCOPY; TREATMENT RESPONSE; TUMOR INVASION; ANALOGS AND DERIVATIVES; ANIMAL; SKIN NEOPLASMS; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ANIMALS; DRUG DELIVERY SYSTEMS; GUANOSINE; HUMANS; NANOPARTICLES; ORGANOPHOSPHONATES; SKIN NEOPLASMS; TISSUE ENGINEERING;

EID: 84893679011     PISSN: 16605527     EISSN: 16605535     Source Type: Journal    
DOI: 10.1159/000354118     Document Type: Article

References (40)

1. Nashan D, Meiss F, Muller M: Therapeutic strategies for actinic keratoses-a systematic review. Eur J Dermatol 2013; 23: 14-32.
2. Stockfleth E, Ferrandiz C, Grob JJ, Leigh I, Pehamberger H, Kerl H: Development of a treatment algorithm for actinic keratoses: a European consensus. Eur J Dermatol 2008; 18: 651-659.
3. Merk HF: Topical diclofenac in the treatment of actinic keratoses. Int J Dermatol 2007; 46: 12-18.
4. Molina BD, Leiro MG, Pulpon LA, Mirabet S, Yanez JF, Bonet LA, Vilchez FG, Delgado JF, Manito N, Rabago G, Arizon JM, Romero N, Roig E, Blasco T, Pascual D, de la Fuente L, Muniz J: Incidence and risk factors for nonmelanoma skin cancer after heart transplantation. Transplant Proc 2010; 42: 3001-3005.
5. Hanke CW, Beer KR, Stockfleth E, Wu J, Rosen T, Levy S: Imiquimod 2.5 and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 3-week cycles. J Am Acad Dermatol 2010; 62: 573-581.
6. Szeimies RM, Radny P, Sebastian M, Borrosch F, Dirschka T, Krahn-Senftleben G, Reich K, Pabst G, Voss D, Foguet M, Gahlmann R, Lubbert H, Reinhold U: Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a prospective, randomized, double-blind, placebocontrolled phase III study. Br J Dermatol 2010; 163: 386-394.
7. Lebwohl M, Swanson N, Anderson LL, Melgaard A, Xu Z, Berman B: Ingenol mebutate gel for actinic keratosis. N Engl J Med 2012; 366: 1010-1019.
8. Lebwohl M, Shumack S, Gold LS, Melgaard A, Larsson T, Tyring SK: Long-term follow-up study of ingenol mebutate gel for the treatment of actinic keratoses. JAMA Dermatol 2013: 1-5.
9. Richartz A, Holtje M, Brandt B, Schafer-Korting M, Holtje HD: Targeting human DNA polymerase alpha for the inhibition of keratinocyte proliferation. 1. Homology model, active site architecture and ligand binding. J Enzyme Inhib Med Chem 2008; 23: 94-100.
10. Zdrazil B, Schwanke A, Schmitz B, Schafer-Korting M, Holtje HD: Molecular modelling studies of new potential human DNA polymerase alpha inhibitors. J Enzyme Inhib Med Chem 2011; 26: 270-279.
11. Schwanke A, Murruzzu C, Zdrazil B, Zuhse R, Natek M, Holtje M, Korting HC, Reissig HU, Holtje HD, Schafer-Korting M: Antitumor effects of guanosine-analog phosphonates identified by molecular modelling. Int J Pharm 2010; 397: 9-18.
12. Tralau T, Riebeling C, Pirow R, Oelgeschlager M, Seiler A, Liebsch M, Luch A: Wind of change challenges toxicological regulators. Environ Health Perspect 2012; 120: 1489-1494.
13. Arkenau HT, Plummer R, Molife LR, Olmos D, Yap TA, Squires M, Lewis S, Lock V, Yule M, Lyons J, Calvert H, Judson I: A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies. Ann Oncol 2012; 23: 1307-1313.
14. Kramer G, Schwarz S, Hagg M, Havelka AM, Linder S: Docetaxel induces apoptosis in hormone refractory prostate carcinomas during multiple treatment cycles. Br J Cancer 2006; 94: 1592-1598.
15. Schafer-Korting M, Holtje M, Korting HC, Holtje HD: Innovative agents for actinic keratosis and nanocarriers enhancing skin penetration. Skin Pharmacol Physiol 2010; 23: 6-14.
16. Baroli B: Penetration of nanoparticles and nanomaterials in the skin: fiction or reality? J Pharm Sci 2010; 99: 21-50.
17. Souto EB, Muller RH: Lipid nanoparticles: effect on bioavailability and pharmacokinetic changes; in Schafer-Korting M (ed): Handbook of Experimental Pharmacology. Heidelberg, Springer, 2010, vol 197: Drug delivery, pp 115-141.
18. Chen H, Chang X, Du D, Liu W, Liu J, Weng T, Yang Y, Xu H, Yang X: Podophyllotoxinloaded solid lipid nanoparticles for epidermal targeting. J Control Release 2006; 110: 296-306.
19. Santos Maia C, Mehnert W, Schaller M, Korting HC, Gysler A, Haberland A, Schafer-Korting M: Drug targeting by solid lipid nanoparticles for dermal use. J Drug Targeting 2002; 10: 489-495.
20. Stecova J, Mehnert W, Blaschke T, Kleuser B, Sivaramakrishnan R, Zouboulis CC, Seltmann H, Korting HC, Kramer KD, Schafer-Korting M: Cyproterone acetate loading to lipid nanoparticles for topical acne treatment: particle characterisation and skin uptake. Pharm Res 2007; 24: 991-1000.
21. Hoeller D, Huppertz B, Roos TC, Poblete Gutierrez P, Merk HF, Frank J, Jugert FK: An improved and rapid method to construct skin equivalents from human hair follicles and fibroblasts. Exp Dermatol 2001; 10: 264-271.
22. Hoeller Obrigkeit DH, Jugert FK, Beermann T, Baron JM, Frank J, Merk HF, Bickers DR, Abuzahra F: Effects of photodynamic therapy evaluated in a novel three-dimensional squamous cell carcinoma organ construct of the skin. Photochem Photobiol 2009; 85: 272-278.
23. Braem C, Blaschke T, Panek-Minkin G, Herrmann W, Schlupp P, Paepenmuller T, Muller-Goyman C, Mehnert W, Bittl R, Schafer-Korting M, Kramer KD: Interaction of drug molecules with carrier systems as studied by parelectric spectroscopy and electron spin resonance. J Control Release 2007; 119: 128-135.
24. Freitas C, Muller RH: Correlation between long-term stability of solid lipid nanoparticles (SLN) and crystallinity of the lipid phase. Eur J Pharm Biopharm 1999; 47: 125-132.
25. Blaschke T, Kankate L, Kramer KD: Structure and dynamics of drug-carrier systems as studied by parelectric spectroscopy. Adv Drug Deliv Rev 2007; 59: 403-410.
26. Lombardi Borgia S, Regehly M, Sivaramakrishnan R, Mehnert W, Korting HC, Danker K, Roder B, Kramer KD, Schafer-Korting M: Lipid nanoparticles for skin penetration enhancement-correlation to drug localization within the particle matrix as determined by fluorescence and parelectric spectroscopy. J Control Release 2005; 110: 151-163.
27. Schafer-Korting M, Bock U, Diembeck W, Dusing HJ, Gamer A, Haltner-Ukomadu E, Hoffmann C, Kaca M, Kamp H, Kersen S, Kietzmann M, Korting HC, Krachter HU, Lehr CM, Liebsch M, Mehling A, Muller-Goymann C, Netzlaff F, Niedorf F, Rubbelke MK, Schafer U, Schmidt E, Schreiber S, Spielmann H, Vuia A, Weimer M: The use of reconstructed human epidermis for skin absorption testing: results of the validation study. Altern Lab Anim 2008; 36: 161-187.
28. ICH: Validation of analytical procedures methodology. ICH Q2B Guideline, 1995.
29. Higuchi WI: Analysis of data on the medicament release from ointments. J Pharm Sci 1962; 51: 802-804.
30. Commandeur S, van Drongelen V, de Gruijl FR, El Ghalbzouri A: Epidermal growth factor receptor activation and inhibition in 3D in vitro models of normal skin and human cutaneous squamous cell carcinoma. Cancer Sci 2012; 103: 2120-2126.
31. Gibson VB, Benson RA, Bryson KJ, McInnes IB, Rush CM, Grassia G, Maffia P, Jenkinson EJ, White AJ, Anderson G, Brewer JM, Garside P: A novel method to allow noninvasive, longitudinal imaging of the murine immune system in vivo. Blood 2012; 119: 2545-2551.
32. Ustaalioglu BB, Bilici A, Ercan S, Seker M, Orcun A, Gumus M: The prognostic importance of changing serum M30 and M65 values after chemotherapy in patients with advancedstage non-small-cell lung cancer. Med Oncol 2013; 30: 551.
33. Ozturk B, Coskun U, Sancak B, Yaman E, Buyukberber S, Benekli M: Elevated serum levels of M30 and M65 in patients with locally advanced head and neck tumors. Int Immunopharmacol 2009; 9: 645-648.
34. Weng YR, Cui Y, Fang JY: Biological functions of cytokeratin 18 in cancer. Mol Cancer Res 2012; 10: 485-493.
35. Ari F, Celikler S, Oran S, Balikci N, Ozturk S, Ozel MZ, Ozyurt D, Ulukaya E: Genotoxic, cytotoxic, and apoptotic effects of Hypogymnia physodes (L.) Nyl. on breast cancer cells. Environ Toxicol, E-pub ahead of print.
36. Schlupp P, Blaschke T, Kramer KD, Holtje HD, Mehnert W, Schafer-Korting M: Drug release and skin penetration from solid lipid nanoparticles and a base cream: a systematic approach from a comparison of three glucocorticoids. Skin Pharmacol Physiol 2011; 24: 199-209.
37. Kuchler S, Wolf NB, Heilmann S, Weindl G, Helfmann J, Yahya MM, Stein C, Schafer-Korting M: 3D-wound healing model: influence of morphine and solid lipid nanoparticles. J Biotechnol 2010; 148: 24-30.
38. Wolf NB, Kuchler S, Radowski MR, Blaschke T, Kramer KD, Weindl G, Kleuser B, Haag R, Schafer-Korting M: Influences of opioids and nanoparticles on in vitro wound healing models. Eur J Pharm Biopharm 2009; 73: 34-42.
39. Atrux-Tallau N, Romagny C, Padois K, Denis A, Haftek M, Falson F, Pirot F, Maibach HI: Effects of glycerol on human skin damaged by acute sodium lauryl sulphate treatment. Arch Dermatol Res 2010; 302: 435-441.
40. Korting HC, Schafer-Korting M: Carriers in the topical treatment of skin disease; in Schafer-Korting M (ed): Handbook of Experimental Pharmacology. Heidelberg, Springer, 2010, vol 197: Drug delivery, pp 435-468.